New research reveals that people who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt traditional lifestyle programs.
Research printed in a prominent health publication demonstrates that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People buying these drugs should be cognizant of the danger of fast weight regain when the treatment concludes," warns expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment mass in about one and a half years.
Analyzing Treatments
The analysis, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team emphasize that people who shed pounds through dieting generally have a slower weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Quick Regain
Doctors believe the mechanism of the drugs accounts for the amplified regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Condition?
The NHS advise the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the likelihood of weight regain, the treatment is often long-term.
This perspective is supported by pharmaceutical companies, who note that the results "underscore the long-term character of excess weight," similar to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication report a powerful return of appetite.
"It felt as if something flipping and you become starving," described one woman.
This difficulty is worsened if users have not established permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is higher among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, experts caution that while the jabs are effective tools for weight loss, they are not a standalone solution and long-term success relies on combined lifestyle support.
